You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3014 results
  1. Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma

    SBC: APIE THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A novel producer cell line for more efficient manufacturing of viral vector systems

    SBC: CLAIRIgene            Topic: 100

    ABSTRACT Significant advances in the specific targeting of delivery vectors and the increased therapeutic efficacy of such vectors for gene delivery have been made, stimulating major interest in the development and commercialization of therapeutic products focused on gene therapy indications. CLAIRIgene LLC focused on the development and optimization of various viral gene-to-cell transfer delivery ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Microfluidic technology platform as a continuous end-line process to inactivate pharmaceuticals

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: NCATS

    PROJECT SUMMARY To achieve the FDA’s required Sterility Assurance Level for use in humans, pharmaceutical products must undergo terminal sterilization or aseptic manufacturing. This can be accomplished using physical or chemical methods such as heat or formaldehyde for simple drug formulations; however, for pharmaceutical products that have more complex drug formulations or that contain biologic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia

    SBC: REGENNOVA, INC.            Topic: R

    Abstract: A Therapeutic Role for Apolipoprotein-E in the Germ Theory of ADP. gingivalis is the keystone bacteria of periodontal disease, the 6th most common infectious disease worldwide. Half of all Americans over the age of 30 and 70% of those over age 65 suffer some degree of P. gingivalis infection associated with gum disease. In a study of 6800 patients with gum disease that were followed for ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel sensor for the real-time measurement of mitral coaptation force

    SBC: MitralPint Inc.            Topic: NHLBI

    Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction

    SBC: NABGEN INC            Topic: NCATS

    Adeno-associated virus (AAV) vectors have been successfully employed in patients with rare neurological diseases. Recently, two AAV based gene therapy drugs have been approved by the FDA, Luxturna been valued at $850,000 with a one-time application for blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. AAV vector mediated gene therapy has shown to be a potentially huge market. Althou ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy

    SBC: Praetego Inc            Topic: NEI

    PROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Leptin Receptor Agonist to Treat Sleep Disordered Breathing

    SBC: Arrevus, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) are the most common types of sleep disordered breathing (SDB). OSA is highly prevalent in the United States, affecting 20-40% of the adult population and more than 50% of individuals with obesity. Approximately 20% of individuals with obesity develop OHS defined as daytime hypercapnia and hypoventilat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text

    SBC: GRAYRAIN, LLC            Topic: NCATS

    PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Structure-based computational engineering of saCas9 PAM requirement

    SBC: ATGC Inc.            Topic: 400

    ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government